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Ipc-PH was defined by a diastolic pressure gradient (DPG: pulmonary artery diastolic pressure minus mean pulmonary artery wedge pressure) <7 mmHg and/or pulmonary vascular resistance (PVR) < _3 Wood units (WU), while Cpc-PH was defined by a DPG > _7 mmHg and/or PVR >3 WU. Patients with Cpc-PH have a worse prognosis compared with patients with Ipc-PH, [4] [5] [6] [7] and this has been attributed mainly to the presence of the pre-capillary pathological obstructive component that affects the distal pulmonary arteries. Heart failure with reduced left ventricular ejection fraction (HFrEF), HF with preserved EF (HFpEF), and valvular heart diseases (VHD) are considered the three largest aetiological subgroups of patients with PH-LHD. 1, 7 In this issue of the European Heart Journal, the article of Bermejo et al. 8 reports the results of the SIOVAC (Sildenafil for Improving Outcomes after VAlvular Correction) study, which is an investigator-driven, academically sponsored, multicentre, randomized, double-blind, placebo-controlled, parallel clinical trial (RCT) in patients with persistent PH after correction of VHD. Two hundred stable adult patients with mean PAP > _30 mmHg, who had undergone a successful valve replacement or repair procedure at least 1 year before, were randomized 1:1 to receive sildenafil (40 mg three times daily (t.i.d), n = 104) or placebo (n = 96) for 6 months. The primary endpoint was the composite clinical score combining death, hospital admission for heart failure, change in functional class, and patient global self-assessment. The relevant message of the SIOVAC study is that treatment with sildenafil was associated with worse clinical outcomes than placebo. This conclusion is not surprising if we consider the lack of favourable clinical outcomes reported by RCTs with sildenafil either in patients with LHD or PH-LHD. 2 The ESC/ERS PH guidelines 1 clearly state that '"the use of PAH-approved therapies is not recommend in patients with PH-LHD"', with a grade of recommendation I and a level of evidence C. As reported also in the paper of Bermejo et al., this has not prevented a large amount of off-label use of sildenafil and of other PAH-approved therapies in patients with PH-LHD. This improper attitude, based mainly on the preliminary results of small single-centre studies, has no pathological, pathophysiological, or haemodynamic rationale or multicentre RCT support ( Figure 1 and Table 1 ).
The pathological changes observed in the distal pulmonary arteries observed in PAH patients are largely different from those observed in PH-LHD patients. In the former, pathological changes predominantly affect the distal pulmonary arteries (diameter < 500 mm) with medial hypertrophy, intimal proliferative and fibrotic changes, and adventitial thickening, with mild to moderate perivascular inflammatory infiltrates and lymphoid neogenesis ( Figure 1 ). In addition, complex lesions such as dilated and plexiform lesions are considered as a hallmark of PAH histology, and correspond to an exuberant Pulmonary vascular disease in patients with PH-LHD ( Figure 1 ) is characterized by enlarged and thickened pulmonary veins, pulmonary capillary dilatation, interstitial oedema, alveolar haemorrhage, lymphatic vessels, and lymph node enlargement. 3 In addition, the pre-capillary circulation may also be involved at the level of distal pulmonary arteries, which may be affected by different degrees of obstructive remodelling such as medial hypertrophy, and intimal fibrosis and proliferation. The presence of this pre-capillary component, which is considered exclusive of the Cpc-PH, form has been described in the past, 3 and confirmed in more recent analyses from biopsies, autopsies, and lungs resections.
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The pathobiological and pathological changes of the distal pulmonary arteries of patients with PAH are the targets for the approved medications, 10 and the relevant diversity of the changes observed in the distal vasculature of PH-LHD subjects does not support a sound rationale for the use of PAH-approved drugs in these patients. The pathophysiology and haemodynamics of PAH patients are characterized by pre-capillary pulmonary hypertension with normal values for left atrial and left ventricular pressures ( Figure 1) . The predominant feature is a severe increase of PVR and of right ventricular afterload. Conversely, in patients with PH-LHD, the initiating mechanism is an increase of left atrial pressure that is transmitted backward to the pulmonary veins, the pulmonary capillaries, and the pulmonary arteries (Figure 1) . The pre-capillary component characterized by mild to moderate obstructive lesions in the distal pulmonary arteries contributes to the increase of PAP in patients with Cpc-PH. Only in these patients are mild to moderate increases of PVR 7 and more prominent increases of right ventricular afterload observed. However, we cannot consider Cpc-PH patients in the same disease spectrum of PAH, as suggested by some authors, 11 due to the striking differences in the originating mechanism (increase of left atrial pressure) and in the pathological changes, and the coexistence of a LHD. The only unifying feature of Cpc-PH and PAH is the increase of PVR, which is clearly insufficient to include them in a similar pathophysiological condition, which theoretically should comprise also all other forms of PH with elevated PVR. 1 The ESC/ERS PH guidelines 1 suggest an evidence-based treatment algorithm for PAH patients, including drugs interfering with the The same drugs have been tested in single and multicentre RCTs in patients with LHD due to HFrEF, HFpEF, and VHD with or without PH. The majority of the RCTs did not show favourable effects in LHD patients (except a few single-centre RCTs), and some raised concerns about safety due to fluid retention. However, the SIOVAC study is the first to clearly report a relevant increase of unfavourable clinical events in patients with PH-LHD treated with PAH-approved drugs such as sildenafil.
In Table 1 , we report the data of 12 RCTs (11 multicentre) with the use of ERA, PA, PDE5i, and sGC stimulators in LHD patients in which safety data have been described in detail, including mortality. The studies involved either HFrEF, HFpEF, or VHD, and at least six RCTs partially or exclusively included patients with PH. It is also conceivable that PH-LHD patients were also in part included in the six RCTs in which PH data were not reported. Interestingly, the mortality was higher in the active drug-treated groups in 9 out of the 12 RCTs, and in 5 out of the 6 RCTs partially or exclusively including PH-LHD patients. Despite the heterogeneity of these RCTs, we believe that these data reinforce the safety concerns raised by the paper by Bermejo et al. on the use of PAH-approved drugs in PH-LHD patients. Therefore, the level of evidence for the ESC/ERS PH guidelines recommendation not to use PAH-approved drugs in PH-LHD patients should be raised from C to B.
The reasons for the unfavorable effects of PAH-approved drugs in PH-LHD patients are unclear and may include the reduction of blood pressure and the consequent fluid retention effect, or the increase of PAWP due to the pre-capillary vasodilatation exerted by these compounds, as shown after the acute administration of nitric oxide. 12 In the study of Bermejo et al., the acute administration of sildenafil lowered pulmonary pressures and increased cardiac output, while long-term administration induced both left and right ventricle dilatation as compared with placebo, suggesting a possible negative inotropic effect of sildenafil in the setting of PH-LHD.
Interestingly, the use of left ventricular assist devices (LVADs) in HFrEF patients with CpcPH (not reversible with pharmacological challenge) is able to reduce the PAWP, PAP, and PVR as soon as after 3 days, and to completely normalize these parameters after 6 weeks. 13 This phenomenon may be explained by the reverse-remodeling of the distal pulmonary arteries' fixed obstructive lesions in response to the prolonged normalization of the PAWP induced by LVADs. In other words, targeting the "primum movens" for the development of both IpcPH and CpcPH, which is the increase of left atrial pressure, seems to be the appropriate strategy in this patient population. In contrast, directly targeting the pulmonary vascular disease is not effective and can be harmful, as shown in the study by Bermejo et al.
While the reduction and possibly the normalization of the PAWP may be feasible in subsets of patients with HFrEF or VHD with available treatments, this is more difficult in HFpEF patients due to the lack of effective drug therapies for this condition. HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; mPAP, mean pulmonary arterial pressure; N/A, not assessed; PAP, pulmonary arterial pressure; sPAP, systolic pulmonary arterial pressure; VHD, valvular heart disease. *Numbers are in mmHg. 
